Entrectinib represented a significant advancement in treating ROS1-positive NSCLC due to its enhanced ability to cross the blood–brain barrier and target CNS metastases, a frequent complication in advanced cases. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.